Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally administered, direct-acting, reversibly binding P2Y12 platelet inhibitor. It is used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* **Acute Coronary Syndrome (ACS):** Treatment of ACS, including unstable angina (UA), non-ST-elevation MI (NSTEMI), and ST-elevation MI (STEMI), in patients who have been managed medically or with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
* **History of Myocardial Infarction (MI):** To reduce the rate of thrombotic cardiovascular events in patients with a history of MI (i.e., ≥1 year prior) who are at high risk for an additional atherothrombotic event.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or until 12 months of therapy is completed, provided no unacceptable bleeding occurs.
* **For patients treated with PCI:** Consider extending therapy beyond 12 months in select high-risk patients, especially if they have not experienced major bleeding.
* **History of MI (≥1 year prior):**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
* **Ticagrelor is NOT indicated for use in pediatric patients.** Safety and effectiveness have not been established.
## Dose Adjustments
* **Hepatic Impairment:**
* **Mild to moderate:** No dose adjustment necessary.
* **Severe:** Use with caution; data are limited.
* **Renal Impairment:** No dose adjustment is recommended in patients with mild, moderate, or severe renal impairment.
* **Elderly:** No dose adjustment is recommended based on age.
## Contraindications
* **Active bleeding:** This includes recent intracranial hemorrhage or active gastrointestinal bleeding.
* **History of intracranial hemorrhage.**
* **Known hypersensitivity** to ticagrelor or any of its components.
## Adverse Effects
* **Most Common:** Dyspnea, bradycardia, dizziness, headache, diarrhea, bruising, rash.
* **Serious:**
* **Bleeding:** Life-threatening, fatal, and major bleeding events (e.g., intracranial, gastrointestinal, intraocular). Risk is increased with concomitant use of anticoagulants.
* **Ventricular pauses:** May occur, particularly in patients with a history of bradycardia or recent MI.
* **Cerebral hemorrhage.**
* **Angioedema.**
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease ticagrelor exposure.
* **Anticoagulants (e.g., warfarin, direct oral anticoagulants):** Increased risk of bleeding. If concomitant use is necessary, use with caution and monitor closely for bleeding.
* **Dual Antiplatelet Therapy (DAPT) with Aspirin:** Ticagrelor is typically used with aspirin. However, continuing aspirin therapy beyond the initial ACS treatment period may increase bleeding risk without substantial additional benefit in some patients.
* **Statins:** Ticagrelor can increase simvastatin and atorvastatin concentrations. Monitor for statin-related adverse effects.
* **Morphine and Opioids:** May reduce ticagrelor absorption and antiplatelet effect. Consider alternative pain management or a different time of administration.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding, especially in patients with increased risk factors.
* **Heart Rate:** Monitor for bradycardia, especially in patients with pre-existing conditions.
* **Renal and Hepatic Function:** Baseline and periodic monitoring may be warranted, especially in patients with significant impairment.
## Clinical Pearls
* Ticagrelor is a **reversible** P2Y12 inhibitor, unlike clopidogrel. This may lead to a faster offset of its antiplatelet effect if discontinued.
* Ticagrelor should be taken **twice daily**, regardless of whether it is a loading or maintenance dose (except for the 60 mg dose for patients with a history of MI).
* The **dyspnea** associated with ticagrelor is usually mild to moderate and often transient. It is not typically a contraindication to therapy, but pulmonary causes should be ruled out.
* For patients unable to swallow whole tablets, ticagrelor tablets can be **crushed** and mixed with water, apple juice, or via a nasogastric tube (ensure tube is flushed with water after administration).
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
